Home › Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
 

Keywords :   


Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial

2015-02-09 18:35:24| Biotech - Topix.net

Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced enrollment of the 700th patient in the NeuVax Phase 3 PRESENT clinical trial. NeuVax is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting.

Tags: present trial phase patient

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
14.05Pampers Introduces Swaddlers 360 Diapers
14.05Rascal + Friends Diapers Unveils Brand Refresh to Rascals
14.05Dr. med. Christine Schrammek Adds At-Home Facial Peel
14.05Atlas Vending and Libresse Provide Menstrual Pads in Malaysia
14.05Aldi UK Introduces Recyclable Butter Packaging Starting Next Month
14.05UK Metals Recycling Company Fined $1.5 Million After Employee Struck by Vehicle on Site
14.05Infinity Recycling's Leading Impact Fund Closes Above Target, Circularity in Plastics One Step Closer
14.05Firmament Recapitalizes Whitecap Waste
More »